NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud® to accelerate innovation across all of its drug development programs. The top-20 global pharmaceutical company will leverage Medidata’s technology platform to bring new insights and knowledge into multiple stages of the Boehringer Ingelheim drug development process, enabling its researchers to conduct faster, more accurate and more cost-effective clinical trials.
